agilon health, inc. (AGL) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. I would now like to pass the conference over to your host, Evan Smith, Investor Relations at Agilent Health. Thank you. You may proceed, Evan. Thank you, Operator. Good afternoon and welcome to the call. With me is Executive Chairman Ron Williams and our CFO, Jeff Schwaneky. Following our prepared remarks, we will conduct a Q&A session. Before we begin, I would like to remind you that our remarks and responses to questions may include forward-looking statements. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with our business. These risks and uncertainties are discussed in our SEC filings. Please note that we assume no obligation to update any forward-looking statements. Additionally, certain financial measures we will discuss in this call are non-GAAP financial measures. We believe that providing these measures helps investors gain a better and more complete understanding of our financial results and is consistent with how management views our financial results. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is available in the Earnings Press Release and Form 8-K filed with the SEC. And with that, let me turn the call over to Ron. Thank you, Evan. Good afternoon, everyone. And thank you for joining us. I'm pleased to be with all of you today. For the third quarter, we reported revenue of $1.44 billion, medical margin of negative $57 million, and adjusted EBITDA of negative $91 million. We are also reinitiating 2025 guidance. While the quarter benefited from the execution of our clinical and quality programs, a...